Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Completed · Phase 3 · Has a placebo group

Conditions studied: Prostate Cancer

In brief

The purpose of this study is to determine if asymptomatic or minimally symptomatic patients with metastatic prostate cancer who have not received chemotherapy live longer when treated with ipilimumab than those treated with a placebo

Key facts

Study ID
NCT01057810
Run by
Bristol-Myers Squibb
People needed
837
Starts
2010-07-01
Expected to finish
2015-07-01
Last updated by the study team
2016-08-18

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.